Osteoarthritis patient cohorts in the dish - personalised cellular drug development tools for osteoarthritis precision medicine

Projektinformationen

O-POINTED

ID Finanzhilfevereinbarung: 868644

DOI 10.3030/868644

Abgeschlossenes Projekt

EK-Unterschriftsdatum 11 Mai 2019

Startdatum 1 Juni 2019

Enddatum 30 November 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

InSCREENeX GmbH
Germany

Ziel

Osteoarthritis is the fastest growing cause of disability worldwide. Still, there is currently no drug available that targets the underlying pathophysiology of osteoarthritis. Clinical trials testing disease-modifying drug candidates consistently fail. This is because osteoarthritis is a complex disease and currently used drug development tools completely disregard patient variability. Consequently, such non-personalised drugs fail to reach high enough response rates in highly variable osteoarthritis patient populations. O-POINTED is the first tool to enable pharma and biotech companies to personalise the osteoarthritis drug development process. O-POINTED is a cellular test system based on personalised and expandable cell lines generated from a cohort of more than 50 osteoarthritis patients. It represents osteoarthritis patient variability including all the main disease phenotypes (bone-, cartilage-, synovium-driven). Compared to conventional test systems, it is easier to use and more relevant, with the unique benefit of representing osteoarthritis patient variability. The combined O-POINTED business model includes a double one-off revenue (product plus consumables) and recurring revenue (milestone-based payments). We estimate that O-POINTED will create €2.9 million revenue and 15 new jobs, 3 years after commercial launch. We have a key customer already testing a minimal viable product of O-POINTED and seek Phase 1 support to evaluate the feasibility of scaling up to a European and Global dimension.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• medical and health sciences › basic medicine › physiology › pathophysiology
• social sciences › economics and business › business and management › business models
• medical and health sciences › health sciences › personalized medicine

Programm/Programme

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Thema/Themen

• EIC-SMEInst-2018-2020 - SME instrument

Aufforderung zur Vorschlagseinreichung

H2020-EIC-SMEInst-2018-2020

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEInst-2018-2020-1

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

InSCREENeX GmbH

• Netto-EU-Beitrag: € 50 000,00
• Adresse: INHOFFENSTRASSE 7 ; 38124 Braunschweig ; Deutschland
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Niedersachsen › Braunschweig › Braunschweig, Kreisfreie Stadt
• Region: Niedersachsen › Braunschweig › Braunschweig, Kreisfreie Stadt
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00